Market Signal Briefing

Bitcoin’s recent sell-off isn’t due to quantum computing fears, because if that were the case, Ether would be soaring, says Bitcoin developer Matt Carallo.

“I strongly disagree with the characterization that Bitcoin's current price is materially, because of some kind of quantum risk,” Carallo told journalist Laura Shin on the Unchained podcast on Thursday.

“If that were true, then Ethereum would be up substantially on Bitcoin,” he added. Ether (ETH) is down 58% since a major crypto market crash in early October, trading at $1,957 at the time of publication.

Carallo’s comments come as several Bitcoiners have argued that fears of quantum computing affecting the blockchain are partly why Bitcoin (BTC) has dropped 46% from its October all-time high of $126,100 to now trade at $67,162, according to CoinMarketCap.

Matt Carallo (right) speaking to Laura Shin (left) on the Unchained podcast. Source: YouTubeEthereum zones in on quantum readinessSome Bitcoin users have accused the blockchain’s developers of not moving quickly enough to make the network quantum-resistant, while the Ethereum Foundation has said it is taking measures to be ready. 

In its protocol update on Wednesday, the Ethereum Foundation outlined long-term post-quantum readiness as part of its broader security initiative.

Carallo said that although quantum computing poses long-term risks to Bitcoin, market makers don’t see it as a pressing short-term threat, arguing that the Bitcoin community is just looking for a scapegoat.

“There are a lot of Bitcoiners who want to blame something, blame someone for lackluster performance.”

Carallo said that a more likely reason for Bitcoin’s price decline is that it is now “competing for capital” in a way it never has before against other technologies such as artificial intelligence.

“AI is super capital-intensive,” he said, adding that it is a “massive new investment class that is substantially competing for capital.”

“There's a lot of interest in value accrual that will happen because of AI in traditional equities,” Carallo said. 

Bitcoiners are of the opposite opinionNot all Bitcoiners agree with Carallo. Capriole Investments founder Charles Edwards said at Cointelegraph’s LONGITUDE event on Feb. 12 that the risk should be priced into Bitcoin until it becomes quantum-resistant.

“Today, you kind of have to start to discount the value of Bitcoin based on that risk until it’s solved,” Edwards said.

Meanwhile, entrepreneur Kevin O’Leary told Magazine in December that using quantum computing to crack Bitcoin may not be the most efficient use of the resources, and there is more upside in using the technology for areas such as medical research.

In May, the world’s largest asset manager, BlackRock, updated the registration statement for its iShares Bitcoin ETF (IBIT) to warn investors of the potential risks to the integrity of the Bitcoin network posed by quantum computing.

Magazine: Bitcoin may take 7 years to upgrade to post-quantum: BIP-360 co-author

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Michael Saylor keeps things upbeat. He told a TV interviewer that the current Bitcoin dip feels milder than past crashes and that a quicker rebound is likely. He even said, “Spring is coming, and Bitcoin is winning.”

Bitcoin Institutional Support Strengthens Outlook According to Saylor, a big reason for his confidence is that banks and big firms are far more involved than they were a few years ago. Reports note fresh banking tools and credit networks aimed at crypto are drawing new capital in.

US President Donald Trump was mentioned by the Strategy big boss as a political force friendly to Bitcoin — a line that will be picked over by both supporters and critics.

We may be in the middle of a crypto winter, but spring is coming — and Bitcoin is winning. pic.twitter.com/jxvzK3XwSN

— Michael Saylor (@saylor) February 17, 2026

Strategy’s Holdings And Price Math Strategy holds 714,644 BTC on its books, bought at an average near $76,056 each. At the moment, Bitcoin trades around $67,900. That gap matters. The roughly $49 billion value sitting in the vault is compared to a company market value that trades around $42.80 billion.

Those raw numbers give weight to Saylor’s claim that the company can handle big swings. He went further, saying that even a fall to $8,000 would leave the holdings enough to cover outstanding debt. That is a strong statement. It was presented as reassurance to investors.

Strategy’s Position And Risk Calculations Reports say Strategy plans to swap its convertible debt into stock within three to six years. The firm has also signaled it will buy more Bitcoin each quarter. How these moves play out depends on markets, financing terms, and timing.

BTCUSD currently trading at $66,294. Chart: TradingView Some analysts think the company’s approach lowers short-term pressure on the share price. Others point out that keeping such a large crypto stash concentrates risk in volatile markets.

Past Cycles Saylor compared the current episode to deeper downturns that came before. That comparison is useful but needs numbers to be fully judged. Historical drops in crypto have been steep at times, which is why claims of a milder slump invite scrutiny.

Other investors look at on-chain flows, macro cash conditions, and bank behavior to decide whether this time is different. Right now, evidence of a fast, broad institutional inflow is mixed.

Outlook And What Could Shift The Story Markets could swing on a few catalysts: changes in lending policy, moves by large funds, or fresh regulatory signals from US authorities. News or shocks could tilt sentiment quickly.

Some market watchers look at 10-year trendlines for context, while others focus on shorter trading indicators. Either way, Saylor’s optimism is clearly tied to a long view and a confident read of current market structure.

Featured image from Long Island Weight Loss Institute, chart from TradingView

Ethereum price found support near $1,905 and recovered some losses. ETH is now consolidating and faces key hurdles near $1,980.

Ethereum is attempting a fresh recovery wave above $1,950. The price is trading below $1,980 and the 100-hourly Simple Moving Average. There is a bearish trend line forming with resistance at $1,985 on the hourly chart of ETH/USD (data feed via Kraken). The pair could start a fresh decline if it stays below the $2,000 zone. Ethereum Price Dips Further Ethereum price failed to stay above $1,950 and started a fresh decline, like Bitcoin. ETH price traded below the $1,935 and $1,920 levels to enter a bearish zone.

Finally, the bulls appeared near $1,900. A low was formed at $1,905, and the price started a recovery wave. There was a move above the $1,945 resistance. The price tested the 38.2% Fib retracement level of the downward move from the $2,038 swing high to the $1,905 low.

Ethereum price is now trading below $1,970 and the 100-hourly Simple Moving Average. If the bulls remain in action above $1,920, the price could attempt another increase. Immediate resistance is seen near the $1,970 level and the 50% Fib retracement level of the downward move from the $2,038 swing high to the $1,905 low.

Source: ETHUSD on TradingView.com The first key resistance is near the $1,985 level. There is also a bearish trend line forming with resistance at $1,985 on the hourly chart of ETH/USD. The next major resistance is near the $2,000 level. A clear move above the $2,000 resistance might send the price toward the $2,050 resistance. An upside break above the $2,050 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $2,120 resistance zone or even $2,150 in the near term.

Another Decline In ETH? If Ethereum fails to clear the $1,985 resistance, it could start a fresh decline. Initial support on the downside is near the $1,935 level. The first major support sits near the $1,905 zone.

A clear move below the $1,905 support might push the price toward the $1,880 support. Any more losses might send the price toward the $1,840 region. The main support could be $1,820.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now above the 50 zone.

Major Support Level – $1,905

Major Resistance Level – $1,985

Kevin O'Leary shared insights into how a 50% bitcoin correction is prompting institutions to recalibrate crypto exposure, rotate capital after steep losses, and factor in emerging quantum computing risks shaping long-term strategy.

Biotechnology stocks and the related ETFs bounced back in significant fashion last year. There’s been some cooling of that trend to start 2026, but that could be just the opportunity some investors have been waiting for to get involved with ETFs such as the ALPS Medical Breakthroughs ETF (SBIO).

SBIO, which holds nearly 90 stocks, is saddled with a modest year-to-date loss, but that might not last long. Not with the biotech investment thesis buoyed by an array of positive factors. Obviously, there’s always the possibility of FDA approvals. That’s a theme to which SBIO is leveraged because it only features shares of companies with drugs or therapeutics in Phase II or III clinical trials.

Fortunately for investors considering biotech equities and ETFs such as SBIO, there’s more to the story than goings on at the FDA.

SBIO: An Alluring 2026 Idea Investors examining SBIO may want to consider what Bank of America Research recently said regarding the broader biotech ETF space.

“We provide a favorable view on biotechnology,” according to the bank. “Fundamental analysts in the space are bullish based on the strong M&A momentum at the end of 2025, and the prospect of a potential patent cliff could sustain deal activity into 2026. Positioning is light, and valuations are acceptable, offering room for upside if sentiment improves.”

Should recent history repeat, SBIO is ideally positioned to benefit because, as Bank of America points, smaller and mid-sized biotech names – the very stocks held by this ETF – were market leaders last year, even beating the S&P 500.

That concept is all the more relevant given that the broader biotech industry, which was once known for consistently trading at multiples above the broader market, currently sports a price-to-earnings (P/E) ratio slightly below that of the S&P 500. The potential good news for SBIO doesn’t end there.

“Patent cliff could lead to strong deal demand, with 23 drugs losing exclusivity by 2030, representing $144B in 2025E sales,” adds Bank of America. “Despite strong returns, biotech ETFs have only seen about a 6% increase in net flows over the past year.”

SBIO, which tracks the S-Network Medical Breakthroughs Index, turned 11 on Dec. 30 and charges an annual fee of 0.50%, or $50 on a $10,000 investment.

For more news, information, and analysis, visit the ETF Building Blocks Content Hub.

Earn free CE credits and discover new strategies

Nvidia has built an AI empire and dominates the AI chip market.

Meta Platforms (META +0.21%) has been one of the most noteworthy names in the artificial intelligence (AI) space over the past couple of years. The company, known for its social media apps, has spoken of its intentions to pursue AI and even bring superintelligence to people around the world. As part of this, Meta has been spending billions of dollars to build out data centers, create large language models, and offer AI features to app users and its advertising customers.

What's the relationship between Meta and AI chip leader Nvidia (NVDA 0.11%)? Meta is one of Nvidia's biggest customers, buying the tech giant's graphics processing units (GPUs) to power key tasks such as the training of its AI models. Though Meta is a significant Nvidia customer, the company has also turned to rival chip designer Advanced Micro Devices in the past, and Meta even makes its own chips.

Meta isn't alone. Some of Nvidia's other customers -- Amazon, for example -- operate in the same way: They seek chips from a variety of sources. And this has prompted investors to worry that Nvidia eventually may lose market share. But, in recent days, Meta made a striking move, and it's excellent news for Nvidia. Let's check it out.

Image source: Getty Images.

An early focus on GPUs First, though, let's start off with a quick summary of Nvidia's business so far. Even before AI became a high-growth industry, Nvidia recognized the potential of the technology and decided to design its GPUs to suit it. This early market presence helped Nvidia build an AI empire that now includes a variety of products from software to networking tools. Importantly, this focus on AI from the earliest days has brought Nvidia expertise and kept the company a step ahead of rivals: Nvidia's GPUs continue to maintain their reputation as the most powerful on the market.

On top of this, Nvidia has committed to updating these chips annually, a move that makes it very difficult for competitors to slip ahead.

Still, investors have worried about the increasing strength of products from rivals such as AMD -- and even moves by Meta, Amazon Web Services (AWS), and others to create their own chips. These new chips are cheaper than Nvidia's GPUs, offering them a clear selling point.

Now, let's turn to the move Meta just made that should relieve investors' concerns. Meta has signed a new deal with Nvidia for the purchase of millions of chips, including GPUs, stand-alone central processing units (CPUs), and networking and security technologies. The value of the deal wasn't released, but CNBC cited Creative Strategies analyst Ben Bajarin as saying it may be worth "tens of billions of dollars."

Today's Change

(

-0.11

%) $

-0.21

Current Price

$

187.77

Nvidia's CPUs for data centers A key point here is that Meta is turning to Nvidia for CPUs, the main processor in a computer, and will use these chips on their own in data centers -- this represents the first big move by Nvidia, a GPU specialist, in the CPU for data centers market.

And the really good news here is that this deal shows the strength of Nvidia's leadership. Though Meta has developed its own chips and could also turn to other players for chips, the company instead has chosen Nvidia as the backbone of its AI infrastructure. Meta has put an enormous focus on AI, so it's clear this company is looking for the very best products to shepherd it along the path -- and once again, it's chosen Nvidia.

So, what does this mean for investors? This doesn't suggest that other AI chip companies won't be successful. There is plenty of room for more than one company to generate significant revenue in this space. But this deal makes it clear that Meta's development of its own chips and even potential moves to buy chips from other companies aren't meant to replace Nvidia. And it's very likely that other Nvidia customers are taking the same route, diversifying supply while still relying on the AI giant.

All of this should relieve worries about Nvidia losing market share -- and spur optimism about Nvidia's next chip launch later this year.

American Coastal Insurance Corporation (ACIC) Q4 2025 Earnings Call Transcript

A Tesla Cyberbeast is on display at the Petersen Automotive Museum in Los Angeles, California, U.S. December 21, 2023. REUTERS/David Swanson Purchase Licensing Rights, opens new tab

CompaniesFeb 19 (Reuters) - Tesla (TSLA.O), opens new tab has reduced the price of Cyberbeast, its most-expensive Cybertruck pickup truck model, to $99,990 from $114,990 in the United States, according to pricing information on the automaker's website on Thursday.

With the recent price cut, Tesla looks to be discontinuing its "Luxe Package" for the model that included Supervised Full Self-Driving and free access to its Supercharger network. The EV maker had added the package to its lineup in August last year when it raised the price of the pickup truck.

Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.

Prices of other Cybertruck models were unchanged.

Earlier this month, Tesla introduced a new all-wheel drive variant of its bestselling Model Y SUV, priced at $41,990, sitting above the cheaper rear-wheel drive "Standard" version.

These trims have become a key part of Tesla's 2026 strategy, lowering entry prices to attract more cost-conscious buyers without waiting for a new mass-market vehicle.

Reporting by Akanksha Khushi in Bengaluru; Editing by Janane Venkatraman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- The Chief Executive Officer of Ecopetrol S.A. ("Ecopetrol") hereby summons all shareholders to the General Shareholders' Meeting (the "Meeting") to be held on Friday, March 27, 2026, starting at 9:00 a.m., at Centro Internacional de Negocios y Exposiciones (Corferias), located on Carrera 37 No. 24 - 67 in Bogota, D.C.

The agenda for the Meeting is expected to be the following:

Safety guidelines Quorum verification Opening of the Meeting by the Chief Executive Officer of Ecopetrol Approval of the agenda Appointment of the chairperson presiding over the Meeting Appointment of the commission responsible for scrutiny and counting of the votes Appointment of the commission responsible for the revision and approval of the minutes of the Meeting Presentation and review of the board of directors' Corporate Governance Report Presentation and review of the 2025 Integrated Management Report Presentation and review of the audited individual and consolidated financial statements as of December 31, 2025 Reading of the Independent Auditor's opinion Approval of the board of directors' Corporate Governance Report Approval of the 2025 Integrated Management Report Approval of the audited individual and consolidated financial statements Presentation and approval of the planned profit distribution for Ecopetrol's shareholders Review and approval of the merger and the merger agreement to be entered into by and between Ecopetrol (as surviving company), and Parque Solar Portón del Sol S.A.S. (as absorbed company) Interventions and miscellaneous The meeting is planned to be held in person and also is also planned to be streamed live on Ecopetrol's website.

The voting process is expected to be conducted electronically. Shareholders are requested to attend the Meeting with their smart mobile device. If a shareholder does not have access to a [device with the required technical specifications][smart mobile device], the company plans to provide an alternative mechanism to enable voting by shareholders.

Beginning on March 5, 2026, shareholders may exercise the right of inspection over Ecopetrol's books and other documents referred to in Articles 446 and 447 of the Commercial Code. Shareholders, their proxies and/or their representatives may request an in-person appointment by emailing [email protected], at least one business day prior to the intended inspection date, in accordance with applicable regulations (available at www.ecopetrol.com.co/asamblea-2026). The aforementioned email address is intended solely and exclusively for scheduling the in-person appointment. Any other concerns or requests must be sent to [email protected].

Pursuant to Article 13 of Law 222 of 1995, we inform shareholders that the merger proposal referred to in item 16 of the agenda is expected to be made available at the Ecopetrol's main domicile, within the legally required time frame. Likewise, we further inform shareholders that said merger does not impose any greater liability upon them nor does it entail any impairment of their economic rights. Therefore, withdrawal rights have not been triggered. Notwithstanding the foregoing, absent or dissenting shareholders who consider that such grounds exist may submit their objection to the merger in accordance with Article 14 of Law 222 of 1995

Shareholders who are unable to attend the Meeting may be represented by proxy. Proxies must meet the requirements established in Article 184 of the Commercial Code. Proxy templates in Spanish and English can be downloaded from the website at www.ecopetrol.com.co/asamblea-2026.eng

For purposes of shareholder representation, the provisions of Legal Circular 006 of 2025 regarding the illegal, unauthorized and unsafe practices by securities issuers shall apply.

Except in cases of legal representation via proxy, Ecopetrol's managers and employees may not represent shares other than their own while they are employed by Ecopetrol. They may also not act as substitute attorneys-in fact. Additionally, they may not vote on the Company's financial statements.

RICARDO ROA BARRAGÁN
Chief Executive Officer

RECOMMENDATIONS

If an individual is acting as a proxy representative, the corresponding proxy form must be submitted in its physical form at registration along with any additional documentation required. Certificates of incorporation and legal representation of the companies must have an issuance date not exceeding one month. To avoid overcrowding, guarantee the adequate participation of all shareholders, the doors of Corferias and registration points will open as of 7:00 a.m. To expedite the registration process and ensure appropriate participation at the If you experience symptoms of acute respiratory infection (cough, fever, sore throat, muscle pain), we recommend that you refrain from attending the Meeting and instead follow it live via streaming. If you choose to attend, please wear a face mask during the Meeting. Shareholders are invited to update their personal information through the Shareholder Service Office´s mailbox and/or phone number and/or the Shareholder portal available on Ecopetrol´s website. Meeting, in the case of individuals representing as proxy multiple shareholders, it is suggested a proxy representative is only responsible for at most 50 proxy forms. Only one helper per shareholder requiring additional assistance will be allowed entry. Only one kit will be provided per shareholder or proxy, regardless of the number of people they represent. The substitution or revocation of the power of attorney will not entitle the delivery of a new kit. Publicity material or any other type of material that might hamper the normal course of the meeting will not be allowed in the facility and their distribution is strictly prohibited. ADDITIONAL INFORMATION IS AVAILABLE AT:
Shareholder Services Office
Telephone Bogotá: +(57) 601307 70 75; rest of the country: +(57) 01 8000 113434 
Email: [email protected]
www.ecopetrol.com.co/asamblea-2026

SOURCE Ecopetrol S.A.

GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript

Proven reserves totaled 300 mmboe, the highest value in the last four years. The reserves replacement ratio reached 121%, driven by the execution of recovery projects. The average reserve life stands at 7.8 years for the Ecopetrol Group. , /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) ("Ecopetrol" and together with its subsidiaries, the "Ecopetrol Group") reported today its proven reserves of oil, condensate, and natural gas (1P reserves), including its share in proven reserves from subsidiaries, estimated based on the standards of the U.S. Securities and Exchange Commission (SEC). 99% of 1P reserves have been certified by three recognized, specialized, and independent firms: Ryder Scott Company, DeGolyer & MacNaughton, and GaffneyCline & Associates.

As of the end of 2025, Ecopetrol Group´s  proven reserves totaled 1,944 billion barrels of oil equivalent (mmboe), representing a 2.7% increase compared to the reserves at the end of 2024.

Although the 2025 Brent reference price (USD 68.64/Bbl) decreased by 13.9% compared to the 2024 price (USD 79.69/Bbl)1, proven reserves contributions reached 300 mmboe and the reserves replacement ratio was 121%, demonstrating the Company's effective management in line with its long–term sustainability and resilience strategy.

The reserves contributions were mainly the result of: (i) enhanced recovery projects with outstanding performance in the Castilla, Chichimene, and Akacias fields; (ii) better operational management in the Rubiales and La Cira–Infantas fields, focused on asset efficiency and value; and (iii)  contracts with the ANH2.

These results represent the highest reserves replacement achieved in the last four years and reflect the capability and commitment of the Ecopetrol Group to generate value across its exploration, development, and production assets, thereby strengthening the sustainability of the Ecopetrol Group.

The following table presents the consolidated balance of proven reserves (1P) for 2025, in million barrels of oil equivalent3:

Concept(SEC)

MMBOE

Proven reserves as of Dec 31, 2024

1,892.7

Revisions*

140.8

Enhanced Recovery

142.6

Extensions and Discoveries

16.1

Purchases/Sales

0.0

Production

–248.0

Proven reserves as of Dec 31, 2025

1,944.2

* "Revisions" includes additions from contracts with the ANH, contributing 100 mmboe."

Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 19,000 employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of ISA's shares, the company participates in energy transmission, the management of real-time systems (XM), and the Barranquilla - Cartagena coastal highway concession. At the international level, Ecopetrol has a stake in strategic basins in the American continent, with Drilling and Exploration operations in the United States (Permian basin and the Gulf of Mexico), Brazil, and Mexico, and, through ISA and its subsidiaries, Ecopetrol holds leading positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, road concessions in Chile, and the telecommunications sector.

This release contains statements that may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All forward-looking statements, whether made in this release or in future filings or press releases, or orally, address matters that involve risks and uncertainties, including in respect of the Company's prospects for growth and its ongoing access to capital to fund the Company's business plan, among others. Consequently, changes in the following factors, among others, could cause actual results to differ materially from those included in the forward-looking statements: market prices of oil & gas, our exploration, and production activities, market conditions, applicable regulations, the exchange rate, the Company's competitiveness and the performance of Colombia's economy and industry, to mention a few. We do not intend and do not assume any obligation to update these forward-looking statements.

For more information, please contact:

Investor Relations Office
Email: [email protected]  

Head of Corporate Communications (Colombia) 
Marcela Ulloa
Email: [email protected] 

1 Brent marker prices referenced in accordance with SEC standards for reserve purposes.
2 Contracts with the ANH enabled the allocation of crude–oil royalties amounting to 95.8 mmboe from the Castilla, Akacias, Caño Sur Este, Chichimene, Rubiales, and Yariguí–Cantagallo fields, under ANH Resolution 0977 of 2025, and 4.5 mmboe from economic rights in Tello – La Jagua.
3 Totals may not exactly equal the sum of the figures due to rounding.

SOURCE Ecopetrol S.A.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Klarna Group plc (NYSE: KLAR) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Klarna's September 2025 initial public offering (the "IPO"), of the important February 20, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So What: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Defendants materially understated the risk that Klarna's loss reserves would materially go up within a few months of the IPO, which they either knew of or should have known of given the risk profile of many individuals agreeing to Klarna's buy now, pay later ("BNPL") loans; and (2); as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

SummaryCompaniesSato replaced by CFO Kenta Kon amid cost pressuresLeadership change reflects Toyota's strategic shiftToyota focuses on lowering break-even point amid tariffsTOKYO, Feb 20 (Reuters) - When Koji Sato was named Toyota CEO in 2023, he appeared to be the man for the moment: a veteran engineer who could give the world’s best-selling automaker a badly needed boost in electric vehicles. But after just three years in the top job, he is being replaced by Chief Financial Officer Kenta Kon, a close ally and former secretary of Chairman Akio Toyoda.

The management change, announced this month, will see Sato become Toyota's (7203.T), opens new tab vice chairman and chief industry officer from April. He delivered record sales and profit and, according to two people familiar with the matter, is regarded by suppliers and investors as a sharp and talented leader. Yet he will have had one of the shortest tenures on record for a Toyota boss.

Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.

In recent months he was absent from some high-profile events that Toyoda attended, leading to speculation among executives about his future, according to three people. Two of the sources said there was no evidence of any falling-out between the men. The people declined to be identified because of the sensitivity of the issue.

Instead, the shake-up reflected Toyoda's thinking that his hand-picked successor was no longer the best fit for the job given mounting cost pressures, three people said. The grandson of Toyota's founder, Toyoda was CEO for almost 14 years prior to Sato.

This account contrasts with the explanation given by Sato at a press conference announcing the change and includes previously unreported details. In an on-stage interview with Toyota's own media outlet, Sato said Toyoda was not involved in the decision.

"Toyota keeps emphasising, over and over, that Akio Toyoda wasn’t involved in the personnel decision," said Seiji Sugiura, a senior analyst at Tokai Tokyo Intelligence Laboratory. "Mr. Sato also says the same thing very carefully – which means he probably was involved."

In a statement to Reuters, Toyota said that Toyoda was not a member of the group that determined executive appointments and not involved in the decision-making. That group had been discussing succession since last year and talks became more concrete when Sato's appointment as chairman of Japan's auto lobby was finalised in late 2025, it said.

After discussing with the group, Sato decided to step down and the proposal was then submitted to the board, Toyota said. Sato contributed to strengthening Toyota's finances and would be taking on multiple roles to address industry-wide challenges, it said.

TOYOTA FOCUSED ON BREAK-EVEN POINTThe leadership change came as the Japanese automaker was increasingly focused on tackling higher costs, partially due to U.S. tariffs, the three people said. Meanwhile, it needed to invest heavily in technology, two of them said. Although EVs were seen as a less immediate threat given cooling demand, Toyota executives were concerned that it was falling behind global rivals in software development, one of them said.

Kon, the incoming CEO, served as Toyoda's secretary for eight years and is known as the architect of a planned buyout of forklift maker Toyota Industries (6201.T), opens new tab. That deal, which would tighten the Toyoda family's grip on a key supplier, has drawn opposition from minority investors who say it lacks transparency and is significantly underpriced.

While automakers have been hit with billions of dollars in added expenses since Trump's tariffs took effect in April, Toyota has an additional burden, having pledged to take on higher costs faced by its suppliers. In recent years the automaker has focused more on its "break-even" point – the number of cars it needs to sell to cover its cost. Toyota sees lowering the break-even as an important gauge of management's ability, one person said.

"Over the past year or so, they’ve been talking a lot about needing to lower the break‑even point," said Sugiura, adding that could spell more cost-cutting under Kon.

Toyota doesn't make the break-even point public. It has a legendary reputation for squeezing costs through its philosophy of "kaizen", or continuous improvement, that identifies seven types of waste, including overproduction and defects.

In its statement, Toyota referred to comments by Kon at the same press conference, where he said Toyota must be "vigilant" to withstand even the most challenging external conditions. As CFO, Kon had been at the forefront of efforts to improve earnings, it said.

Kon is also CFO of Toyota's technology subsidiary, Woven by Toyota, where Toyoda's son, Daisuke, is a senior vice president.

Toyota said it expected to spend 360 billion yen ($2.3 billion) in the current financial year to help suppliers. It did not see the outlay as just a cost, it said, but an investment in improving competitiveness.

Toyota this month raised its full-year profit outlook by 12%, helped in part by cost-cutting. It has fared better than other automakers, thanks to its contrarian bet on gasoline-electric hybrids that now looks prescient.

($1 = 153.6700 yen)

Reporting by Maki Shiraki and Norihiko Shirouzu; Additional reporting by Daniel Leussink; Writing by David Dolan; Editing by Stephen Coates

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Opendoor Technologies Inc. (OPEN) Q4 2025 Earnings Call Transcript

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share. The gross proceeds to Candel from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about February 23, 2026, subject to customary closing conditions. In addition, Candel has granted the underwriters a 30-day option to purchase up to 2,752,293 additional shares of its common stock at the public offering price, less the underwriting discount.

Candel intends to use the net proceeds from the offering to complete critical launch readiness, medical affairs, pre-commercialization, and commercial activities for aglatimagene besadenovec (CAN-2409 or aglatimagene) in early, localized prostate cancer, ongoing development costs related to the phase 3 trial of aglatimagene in non-small cell lung cancer (NSCLC), and for general corporate purposes.

Citigroup, Cantor, and Stifel are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as lead manager for the offering. H.C. Wainwright & Co. and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the SEC) on August 14, 2025 and declared effective by the SEC on August 22, 2025. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-800-831-9146; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, New York 10022 , or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in NSCLC and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed, localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Forward-Looking Statements

Various statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Candel’s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Candel’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled “Risk Factors” in the prospectus supplement and registration statement referenced above, Candel’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 13, 2025 with the SEC and subsequent filings with the SEC including Candel’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Candel will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Candel undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Investor Contact:
Theodore Jenkins  
VP, Investor Relations and Business Development 
Candel Therapeutics, Inc. 
[email protected]

Media Contact:
Ben Shannon
Vice President
ICR Westwicke
[email protected]

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026.

SO WHAT: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Enphase overstated its ability to manage its channel inventory; (2) Enphase overstated its ability to mitigate effects arising from the termination of the Residential Clean Energy Credit; (3) accordingly, Enphase overstated its financial and operational prospects; and (4) as a result, Enphase’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Mativ Holdings, Inc. (MATV) Q4 2025 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript

New York, New York--(Newsfile Corp. - February 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.

On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, approximately $43 million below the $933 million consensus estimate. The EP segment has been positioned as the primary growth engine for the company, driven by its FARAPULSE pulsed field ablation system and related cardiac rhythm management products.

The electrophysiology market represents one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential replacement for traditional thermal ablation procedures. Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has invested heavily in expanding manufacturing capacity and physician training programs. The company projected that global PFA penetration would reach 50% by the end of 2025 and grow to approximately 80% by 2028.

During the Q3 2025 earnings call on October 22, 2025, CEO Mike Mahoney stated the company was "guiding to organic growth of 11% to 13% for fourth quarter '25" and expressed that the company was "incredibly proud of our EP performance, with third quarter sales growing 63%." The company had emphasized EP growth rates of 94% in Q2 2025 and 63% in Q3 2025.

During the first Q&A exchange following the Q4 2025 earnings release, analysts noted the street was expecting approximately 25% EP growth for the quarter. Management's discussion indicated confidence in only approximately 15% growth going forward, representing a significant gap between market expectations and the company's internal outlook.

Following the earnings release, BSX shares fell 17.5% with the stock reaching a 52-week low of $75.50.

If you suffered a loss on your Boston Scientific Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284629

Source: Levi & Korsinsky, LLP

Five9, Inc. (FIVN) Q4 2025 Earnings Call Transcript

February 19, 2026 – TheNewswire - Golden Cariboo Resources Ltd. (CSE:GCC) (OTC:GCCFF) (WKN:A402CQ) (FSE:3TZ) (the “Company”) provides additional information to that included in the news release of February 11, 2026 regarding Interactive Offers.  Interactive Offers provides digital marketing and promotional services through online channels, including digital campaigns and content placement. Interactive Offers is arm’s length to the Company with no prior affiliation, ownership interest or other relationship.  Interactive Offers can be contacted at:

  Interactive Offers, LLC 

Address: 327 Plaza Real, Suite 319, Boca Raton, FL 33432, USA

Phone: +1 (844) 563-3377

Email: [email protected]

Website: www.interactiveoffers.com

    About Golden Cariboo Resources Ltd.

  Golden Cariboo Resources Ltd. is rediscovering the Cariboo Gold Rush by proceeding with highly targeted drilling and trenching programs on its Quesnelle Gold Quartz Mine property which is bordered by Osisko Development (NSE:ODV/TSXV:ODV), partly intertwined with them at the north end of the Cariboo Gold Project, and located along a favourable corridor adjacent to the Spanish and Eureka thrust faults over a 94,899 hectare (234,501 acre) area. Historically, over 101 placer gold creeks on the 90-kilometer (56 mile) trend, from the Cariboo Hudson mine north to the Quesnelle Gold Quartz Mine property, have recorded production with successful placer mining continuing to this day.

  Golden Cariboo’s Quesnelle Gold Quartz Mine property is 4 kilometers (2.5 miles) northeast of, and road accessible from, Hixon in central British Columbia. The Property includes the Quesnelle Quartz gold-silver deposit, which was discovered in 1865 and developed over a footprint of about 150m x 150m (< 6 acres) at the Main zone straddling Hixon Creek. Overall, the geological setting of the gold mineralization at the Company’s Quesnelle Gold Quartz Mine property shows strong similarities with the Spanish Mountain gold deposit, situated 120 km (75 miles) towards the southeast along the same geological trend. As a sediment-hosted vein (SHV) deposit, the Spanish Mountain deposit is considered to belong to the epizonal orogenic subclass of gold deposits which include some of the world’s largest deposits such as Muruntau, Uzbekistan and Bendigo, Australia.

   For further information please contact:

  GOLDEN CARIBOO RESOURCES LTD      

“J. Frank Callaghan”       

  J. Frank Callaghan, President & CEO

Tel:  604-669-6463

    

  VISIT OUR WEBSITE FOR MORE DETAILS

www.goldencariboo.com

LIKE AND FOLLOW

Instagram, Facebook, X (Twitter), LinkedIn

    Neither the “CSE” Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

  Cautionary Statements:

  This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and plans of the Company. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding; the expectation that the Company will receive all necessary exemptions and approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed, or at all; the expectation that the proceeds will be used for property exploration and for general working capital; the Company’s exploration plans with respect to its Quesnelle Gold Quartz Mine property; and the anticipated participation of the insider in the Offering.

  Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that the Company will receive all necessary exemptions and approvals to complete the Offering; that the Company will complete the Offering on the terms disclosed, or at all; that the proceeds will be used for property exploration and for general working capital; that the Company will have the resources required to proceed with its exploration plans; that the Company will not run into regulatory or other barriers in carrying out its business plans; that the insider will participate in the Offering, on the terms and conditions and in the amount currently expected by management; and that the Company will be able to rely on the exemption from the formal valuation and minority shareholder approval requirements on the basis anticipated.

  Additionally, forward-looking information involve a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that the Company will not receive the necessary exemptions and approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; that the Company will be unable to use the proceeds for property exploration and for general working capital; that the Company may incur unanticipated costs; that the Company may not have the resources required to pursue its exploration plans; that the Company’s operations could be adversely affected by possible future government legislation policies and controls or by changes in applicable laws and regulations; that the insider may not participate in the Offering on the terms and conditions and in the amount currently expected by management, or at all; and that the Company may not be able to rely on the exemption from the formal valuation and minority shareholder approval requirements on the basis currently expected. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. Neither the Company nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this news release. Neither the Company nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this news release by you or any of your representatives or for omissions from the information in this news release.

  The forward-looking statements herein speak only as of the date they were originally made. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Savers Value Village (SVV - Free Report) reported $464.67 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 15.6%. EPS of $0.15 for the same period compares to $0.10 a year ago.

The reported revenue represents a surprise of -0.01% over the Zacks Consensus Estimate of $464.69 million. With the consensus EPS estimate being $0.16, the EPS surprise was -3.23%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Savers Value performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Comparable Store Sales Growth - Total: 5.4% versus 4.3% estimated by three analysts on average.Number of Stores - Total: 367 versus the two-analyst average estimate of 376.Number of Stores - United States: 179 versus the two-analyst average estimate of 186.Number of Stores - Canada: 170 versus 172 estimated by two analysts on average.Comparable Store Sales Growth - United States: 8.8% compared to the 6.4% average estimate based on two analysts.Comparable Store Sales Growth - Canada: 0.7% versus the two-analyst average estimate of 0.3%.U.S. Retail: $265.88 million versus $258.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20.6% change.Other: $33.9 million versus the three-analyst average estimate of $34.18 million. The reported number represents a year-over-year change of +11.5%.Canada Retail: $164.89 million versus the three-analyst average estimate of $161.06 million. The reported number represents a year-over-year change of +9.1%.View all Key Company Metrics for Savers Value here>>>

Shares of Savers Value have returned +1.1% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

RingCentral (RNG - Free Report) reported $644.03 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.8%. EPS of $1.18 for the same period compares to $0.98 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $642.29 million, representing a surprise of +0.27%. The company delivered an EPS surprise of +3.69%, with the consensus EPS estimate being $1.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how RingCentral performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Gross Margin - Non-GAAP Other: -10.6% versus the four-analyst average estimate of -9.5%.Gross Margin - Non-GAAP Subscriptions: 80.4% versus the four-analyst average estimate of 80.6%.Revenues- Subscriptions: $622.22 million versus the four-analyst average estimate of $621.84 million. The reported number represents a year-over-year change of +5.5%.Revenues- Other: $21.82 million compared to the $20.44 million average estimate based on four analysts. The reported number represents a change of -12.2% year over year.View all Key Company Metrics for RingCentral here>>>

Shares of RingCentral have returned +14.1% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

PTC Therapeutics (PTCT - Free Report) reported $164.68 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 22.8%. EPS of -$1.67 for the same period compares to -$0.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $304.72 million, representing a surprise of -45.96%. The company delivered an EPS surprise of -700.58%, with the consensus EPS estimate being -$0.21.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Net product revenue: $183.99 million versus the four-analyst average estimate of $174.53 million. The reported number represents a year-over-year change of +18.9%.Revenues- Royalty revenue: $79.39 million compared to the $70.77 million average estimate based on four analysts. The reported number represents a change of +36.5% year over year.Revenues- Net product revenue- Translarna: $39 million compared to the $40.42 million average estimate based on three analysts. The reported number represents a change of -58.4% year over year.Revenues- Net product revenue- Emflaza: $27.1 million versus $29.58 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -46.3% change.Revenues- Collaboration and license revenue: $-0.07 million versus $118.82 million estimated by two analysts on average.View all Key Company Metrics for PTC Therapeutics here>>>

Shares of PTC Therapeutics have returned -8.8% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

FORT PIERCE, FL / ACCESS Newswire / February 19, 2026 / Twin Vee PowerCats Co. (Nasdaq:VEEE), ("Twin Vee" or the "Company"), a manufacturer, distributor, and marketer of power sport boats, today announced the pricing of a best-efforts public offering of 6,383,000 shares of common stock. Each share of common is being sold at a public offering price of $0.47 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be approximately $3 million. The offering is expected to close on February 23, 2026, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

ThinkEquity is acting as the sole placement agent for the offering.

A registration statement on Form S-1 (File No. 333-292661) relating to the securities was filed with the Securities and Exchange Commission ("SEC") and became effective on January 30, 2026, and a post-effective amendment to the registration statement became effective on February 13, 2026. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Twin Vee PowerCats Co.

Twin Vee PowerCats Co. manufactures a range of boats under the Twin Vee and Bahama Boat Works brands, designed for activities including fishing, cruising, and recreational use. Twin Vee PowerCats are recognized for their stable, fuel-efficient, and smooth-riding catamaran hull designs. Twin Vee is one of the most recognizable brand names in the catamaran sport boat category and is known as the "Best Riding Boats on the Water™." Bahama Boat Works is an iconic luxury brand long celebrated for its unmatched craftsmanship, timeless aesthetic, and dedication to producing some of the finest offshore fishing vessels.

The Company is located in Fort Pierce, Florida, and has been building and selling boats for 30 years.

Learn more at twinvee.com and bahamaboatworks.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" and similar expressions that are intended to identify forward-looking statements and include statements regarding the timing and completion of the proposed offering and the intended use of proceeds.

These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to consummate the offering and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the Company's Quarterly Reports on Form 10-Q, the Company's Current Reports on Form 8-K and subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
Glenn Sonoda
[email protected]

SOURCE: Twin Vee PowerCats Co.